Hippisley-Cox J, Coupland C. Heart 2010;96:939-47
description
Transcript of Hippisley-Cox J, Coupland C. Heart 2010;96:939-47
Hippisley-Cox J, Coupland C. Heart 2010;96:939-47
Baseline characteristics of new users of statins and non-users of statins aged 30-84 years in the QResearch derivation and THIN validation cohorts
Hippisley-Cox J, Coupland C. Heart 2010;96:939-47
Adjusted HRs (95% CI) for moderate to severe myopathyModels also adjusted for age and body mass index
Hippisley-Cox J, Coupland C. Heart 2010;96:939-47
Validation statistics for each model in the THIN and QResearch validation cohorts
Hippisley-Cox J, Coupland C. Heart 2010;96:939-47
Adjusted HRs (95% CI) for acute renal failure Models also adjusted for age and body mass index
Hippisley-Cox J, Coupland C. Heart 2010;96:939-47
Adjusted HR (95% CI) for moderate/serious
liver dysfunction
Models also adjusted for age and body mass index
Hippisley-Cox J, Coupland C. Heart 2010;96:939-47
Adjusted HR (95% CI) for cataract
Models also adjusted forage and body mass index
Hippisley-Cox J, Coupland C. Heart 2010;96:939-47
Predicted to observed risk of each outcome using the QResearch database
Hippisley-Cox J, Coupland C. Heart 2010;96:939-47
Numbers needed to harm (NNH) or numbers needed to treat (NNT) and numbers of extra or prevented cases, for each outcome over 5 years in patients aged 35-74 free of
cardiovascular disease at baseline with QRISK2 score of 20%+
Hippisley-Cox J, Coupland C. Heart 2010;96:939-47